Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2020-04-27 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2019年年度报告
Annual Report Classification · 100% confidence The document is titled "康芝药业股份有限公司 2019 年年度报告全文" which translates to "Honz Pharmaceutical Co., Ltd. 2019 Annual Report Full Text." It contains detailed sections including company overview, financial data, business summary, management discussion, and other comprehensive information typical of a full annual report. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes financial figures, business segments, and detailed operational data for the fiscal year 2019. There is no indication that this is merely an announcement or a presentation. Therefore, this document fits the definition of an Annual Report (10-K). FY 2019
2020-04-27 Chinese
第五届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the fifth board of directors' fourth meeting of Kangzhi Pharmaceutical Co., Ltd. It includes approvals of various reports such as the 2019 annual report, financial statements, profit distribution plan, internal control reports, social responsibility report, and other corporate governance matters. The document references the 2019 fiscal year and mentions that these reports will be submitted to the 2019 annual shareholders' meeting for approval. The content is typical of a board meeting resolution announcement rather than the full annual report itself. The document length is 5538 characters, which is substantial but the text is primarily about board meeting decisions and approvals, not the full financial report. Therefore, this document is best classified as Board/Management Information (MANG), as it announces board meeting resolutions and management decisions rather than being the full annual report or financial statements themselves.
2020-04-27 Chinese
海通证券股份有限公司关于公司2019年度募集资金存放与实际使用情况的专项核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the special audit opinion on the 2019 annual fundraising funds deposit and actual usage of Kangzhi Pharmaceutical Co., Ltd. It includes extensive financial data on the amount raised, usage, management, and compliance with regulatory requirements. The document references regulatory guidelines related to fundraising and securities issuance, and it contains detailed tables and explanations about the use of funds, investment projects, and audit opinions. The content is focused on the management and use of raised capital funds, which aligns with a Capital/Financing Update. It is not an annual report, earnings release, or audit report in the traditional sense but a specialized report on fundraising and capital usage. The length and detail confirm it is the report itself, not just an announcement. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-04-27 Chinese
2019年度社会责任报告
Environmental & Social Information Classification · 100% confidence The document is titled '2019 年度社会责任报告' which translates to '2019 Annual Social Responsibility Report'. It covers topics such as the company's social responsibility practices, environmental and social initiatives, safety production, energy saving and emission reduction, green office practices, and community engagement. The content is focused on Environmental, Social, and Governance (ESG) factors and sustainability efforts rather than financial performance or regulatory compliance. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, the document fits the category of Environmental & Social Information (SR).
2020-04-27 Chinese
2019年度独立董事述职报告（郑欢雪）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2019" from 康芝药业股份有限公司. It details the independent director's attendance at board and shareholder meetings, opinions on various board resolutions, committee work, on-site inspections, investor protection efforts, training, and other duties performed during the year 2019. The content is a detailed narrative of management and board activities, opinions, and governance-related work rather than a financial report or audit. It does not contain financial statements or earnings data, nor is it a simple announcement or certification. This type of document fits best under Board/Management Information (MANG), as it relates to board member activities and governance reporting by a director.
2020-04-27 Chinese
2019年度独立董事述职报告（吴清和）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report for 2019" from 康芝药业股份有限公司. It details the independent director's activities, attendance at board and shareholder meetings, opinions on various board resolutions, committee work, on-site inspections, investor protection efforts, and training during the 2019 fiscal year. The content is a detailed narrative of management and board oversight activities rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it a brief announcement or proxy solicitation. It is a management-related report focusing on board and director activities and governance oversight. Therefore, the document fits best under Board/Management Information (MANG).
2020-04-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.